UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. Vandana Singh FDA Approves UCB's Psoriasis Drug ...
In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback